Nanotechnology contributions to the pharmacotherapy of pediatric HIV: A dual scientific and ethical challenge and a still pending agenda

Nanomedicine

Volumn 5, Issue 6, 2010, Pages 833-837

  Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b National Science Research Council CONICET   (Argentina)

Author keywords

cost viable liquid formulations; efavirenz; ethical affordability; neglected diseases; pediatric HIV; scalable liquid formulations

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GLYCOPROTEIN P;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; EUROPE; GERIATRIC PATIENT; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; NANOTECHNOLOGY; NATURAL CHILDBIRTH; NONHUMAN; NORTH AMERICA; PATIENT COMPLIANCE; PEDIATRICS; PRIORITY JOURNAL; SOCIOECONOMICS; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; NANOTECHNOLOGY;

EID: 77956078374     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.64     Document Type: Editorial

References (25)

1. HIV/AIDS in Europe: Moving From Death Sentence to Chronic Disease Management. Matic S, Lazarus JV, Donoghoe MC (Eds). World Health Organization Regional Office for Europe. World Health Organization Publications, Geneva, Switzerland (2006).
2. Standing JF, Tuleu C: Paediatric formulations -getting to the heart of the problem. Int. J. Pharm. 300, 56-66 (2005).
3. Committee on Pediatric AIDS (Section on international child health): Increasing antiretroviral drug access for children with HIV infection. Pediatrics 119, 838-845 (2007).
4. Panel of Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents to treat HIV infection in pediatric patients. Pan. Am. J. Public Health 10, 426-435 (2001).
5. Shah CA: Adherence to high activity antiretroviral therapy (HAART) in pediatric patients infected with HIV: issues and interventions. Indian J. Pediatr. 74, 55-60 (2007).
6. Choonara I, Conroy S: Unlicensed and off-label drug use in children: implications for safety. DrugSaf. 25, 1-5 (2002).
7. Nunn T, Williams J: Formulation of medicines for children. Br. J. Clin. Pharmacol. 59, 674-676 (2005).
8. Eileen Kairuz T, Gargiulo D, Bunt C et al.: Quality, safety and efficacy in the 'off-label' use of medicines. Curr. Drug Safety 2, 89-95.
9. Barrueco N, Castillo I, Ais A et al.: Program of pharmaceutic attention to pediatric patients in antiretroviral therapy. Farm. Hosp. 29, 367-374 (2005).
10. Wintergerst U, Hoffmann F, Jansson A et al.: Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. Antimicrob. Chemother. 61, 1336-1339.
11. Gao JZ, Hussain MA, Motheram R et al.: Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J. Pharm. Sci. 96, 2970-2977 (2007).
12. Fabbiani M, Di Giambenedetto S, Bracciale L et al.: Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J. Antimicrob. Chemother. 64, 109-117 (2009).
13. Csajka C, Marzollini C, Fattinger K et al.: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharm. Ther. 73, 20-30 (2003).
14. Aarnoutse R, Schapiro JM, Bouchr CAB et al.: Therapeutic drug monitoring. Drugs 63, 741-753 (2003).
15. van Luin M, Gras L, Richter C et al.: Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J. Acquir. ImmuneDefic. Syndr. 52, 240-245 (2009).
16. Sellers RS, Antman M, Phillips J et al.: Effects of Miglyol 812 on rats after 4 weeks of gavage as compared with methylcellulose/ Tween 80. Drug. Chem. Toxicol. 28, 423-432 (2005).
17. Dionisio D, Gass R, McDermott P et al.: What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? CurrentHIVRes. 5, 155-187 (2007).
18. Chiappetta DA, Hocht C, Taira C, Sosnik A: Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine (Lond.) 5, 11-23 (2010).
19. Chiappetta DA, Hocht C, Sosnik A: A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate paediatric management of the anti-HIV therapy. Curr. HIVRes. 8, 23-31 (2010).
20. Sosnik A, Amiji M: Nanotechnology solutions for infectious diseases in developing nations. Adv. Drug Del. Rev. 62, 375-377 (2010).
21. AIDS epidemic update 2007, World Health Organization www.who.int/hiv/ epiupdates/en/index.html (Accessed May 2010)
22. AIDS orphans, AVERT Organization www.avert.org/aidsorphans.htm (Accessed May 2010)
23. The US President's Emergency Plan for AIDS Relief (PEPFAR). Pediatric treatment and care www.pepfar.gov/press/86524.html (Accessed May 2010)
24. WHO/Make medicines child size www.who.int/childmedicines/en (Accessed May 2010)
25. Administracion Nacional de Medicamentos, Alimentos y Tecnologfa Medica (ANMAT), Ministry of Health, Argentina www.anmat.gov.ar (Accessed May 2010)